Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac

Authors:

Rapisa Nantane, MD^{a,b}, Puneyavee Aikphaibul, MD^{a,c}, Peera Jaru-Ampornpan, PhD^d, Pimpayao Sodsai, PhD^e, Orawan Himananto, PhD^f, Tuangtip Theerawit, RN^a, Jiratchaya Sophonphan, MSc^g, Punyot Tovichayathamrong, MD^h, Kasama Manothummetha, MD^h, Tysdi Laohasereekul, MD^h, Narin Hiransuthikul, MD, PhDⁱ, Nattiya Hirankarn, MD, PhD^e, Thanyawee Puthanakit, MD^a on behalf of the Study Team*

^a Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

^b Pediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

^c Division of Pediatric Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

^d Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)

^e Center of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

^f Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)

^g The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand

^h Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

ⁱ Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

Corresponding author: Thanyawee Puthanakit, MD

Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University
1873, Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.

Telephone: (+66)2-2564930

E-mail: thanyawee.p@chula.ac.th

*Additional study team members are listed.

Highlights:

- Intradermal AZD1222 booster vaccine gave comparable short-term immunogenicity but lower 90-day immunogenicity with conventional intramuscular vaccine.

- 45 • Lower systemic but higher local reactogenicity was found in intradermal AZD1222
- 46 booster vaccine.
- 47 • Blister and pruritus could be seen after intradermal AZD1222 booster vaccine.
- 48
- 49 Word counts: 3295, Abstract 300
- 50 41 References, 2 Tables, 3 Figures, 1 Supplementary Table, 1 Supplementary Figure
- 51 Thai clinical trial registry: TCTR 20210817003

Abstract

Background

Currently, booster dose is needed after 2 doses of inactivated COVID-19 vaccine. With limited resource and shortage of COVID-19 vaccine, intradermal(ID) administration might be a potential dose-sparing strategy.

Objective

To determine antibody response and reactogenicity of ID ChAdOx1 nCoV-19 vaccine(AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose CoronaVac(SV) in healthy adult.

Methods

This is a prospective cohort study of adult aged 18-59 years who received 2-dose SV at 14-35 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1×10^{10} viral particles,0.1ml). Antibody responses were evaluated by surrogate virus neutralization test(sVNT) against wild type and delta variant and anti-spike-receptor-binding-domain immunoglobulin G(anti-S-RBD IgG) at prior, day14 or 28, and day90 post booster. Solicited reactogenicity was collected during 7 days post-booster. Primary endpoint was the differences of sVNT against delta strain $\geq 80\%$ inhibition at day14 and 90 compared with the parallel cohort study of 0.5-ml intramuscular(IM) route.

Results

From August2021, 100 adults with median(IQR) age of 46(41-52) years participated. At baseline, geometric means(GMs) of sVNT against delta strain prior to booster were 22.4%inhibition(95%CI 18.7-26.9) and of anti-S-RBD IgG were 109.3(95.4-125.1)BAU/ml. GMs of sVNT against delta strain were 92.9%inhibition(95%CI 87.7-98.3) at day14 and

73.1% inhibition (66.7-80.2) at day 90 post ID booster. The differences of proportion of participants with sVNT to delta strain $\geq 80\%$ inhibition in ID recipients versus IM were +4.2% (95% CI -2.0 to 10.5) at day 14, and -37.3% (-54.2 to -20.3) at day 90. Anti-S-RBD IgG GMs were 2037.1 (95% CI 1770.9-2343.2) at day 14 and 744.6 (650.1-852.9) BAU/ml at day 90, respectively. Geometric mean ratios (GMRs) of anti-S-RBD IgG were 0.99 (0.83-1.20) at day 14, and 0.82 (0.66-1.02) at day 90. Only 18% reported feverish, compared with 37% of IM ($p=0.003$). Only 18% reported feverish, compared with 37% of IM ($p=0.003$). Common reactogenicity was erythema (55%) at injection site while 7% reported blister.

Conclusion

Low-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity.

Keywords: SARS-CoV2 vaccine, booster dose, AZD1222, Neutralizing antibody titer, anti-SARS CoV2 IgG, CoronaVac vaccine, ChAdOx1 nCoV-19 vaccine, intradermal

Abbreviations:

BAU = Binding-antibody unit

BMI = Body mass index

CMI = Cell-mediated immunity

ELISpot = Enzyme-linked immunospot

GM = Geometric mean

GMR = Geometric mean ratio

- 97 ID = Intradermal
- 98 IM = Intramuscular
- 99 PBMC = Peripheral blood mononuclear cell
- 100 SFU = Spot forming unit
- 101 S-RBD = Spike receptor binding domain
- 102 sVNT = Surrogate virus neutralization test

1. Introduction

Global report of Coronavirus disease (COVID-19) infection was over 250 million cases with more than 5 million deaths [1], despite over 7 billion doses of vaccination have been administered. In Thailand, as of November 2021, more than 2 million reported COVID-19 infection with over 20,000 deaths. Inactivated COVID-19 vaccine, CoronaVac (Sinovac Life Sciences, Beijing, China), was used for mass vaccination in several countries e.g., Thailand, China, Brazil, and Chile. Effectiveness of CoronaVac for prevention of COVID-19 was 65.9% from study in Chile [2] and 36.8% from study in Brazil [3]. With the rising of delta variant (B.1.617.2) of SAR-CoV-2 globally, the neutralizing activity induced by CoronaVac declined [4]. Hence, heterologous prime boost vaccination may provide better immunogenicity. With AZD1222 followed by BNT162b2 heterologous prime boost vaccination, this vaccination strategy provided highest T cell reactivity compared with homologous vaccination [5, 6].

Standard administration of currently available COVID-19 vaccine is via intramuscular injection. Routes for vaccine administration could be intramuscular (IM), intradermal (ID) in which efficacy is related to the immunogenicity [7]. ID administration offers potential dose-sparing benefit compared with intramuscular administration, rabies vaccination as example. ID vaccination is a technique in which the vaccine is administered into dermis which is rich in antigen presenting cells such as dermal dendritic cells [8]. Because of the abundance of antigen presenting cells in skin, ID administration required less antigenic dose (usually 20%-30% of standard dose) to induce immune responses than standard IM vaccination. Many studies showed effective immune response by ID vaccination including influenza, rabies, hepatitis B, Bacille Calmette-Guerin (BCG), and polio vaccination [7, 9-12]. For influenza vaccine, a systematic review and meta-analysis showed comparable seroprotection rates for 9- μ g ID with 15- μ g IM

injection with higher local adverse event particularly erythema and swelling [9]. For rabies vaccine, ID schedules offer advantages through savings in costs, doses and time as recommended by WHO and also approved use on label of vaccine [12].

Fractionated-dose ID COVID-19 vaccine is the potential for rapid achievement of herd immunity based on other vaccines reported [7]. Study of one-tenth dose of mRNA-1273 ID vaccination showed comparable anti-spike IgG and anti-RBD IgG responses to conventional IM vaccination at 2 weeks post primary vaccination series [13]. However, one-fifth dose of BNT162b2 ID booster in healthy Thai adult post 2-dose CoronaVac failed to boost T cell response at 14 days, despite robust neutralizing antibodies response [14]. A case report of ID AZD1222 after 2 doses of CoronaVac showed increase of antibodies and T cell responses against spike protein which neutralizing antibody increased to almost 100% with minimal local reaction at 2-3 weeks after booster [15].

This study aims to evaluate immunogenicity and reactogenicity of ID AZD1222 booster dose in adults who had received 2 doses of CoronaVac.

2. Methods

2.1 Study design and participants

This study was conducted at Chulalongkorn University Health Center, Faculty of Medicine, Chulalongkorn University, Bangkok Thailand. This is a prospective cohort study. The participants who aged 18 – 59 years old and received two doses of CoronaVac for at least 60 days, 14 – 35 days apart were included in this study. The exclusion criteria were receiving any immunosuppressants or blood products within 3 months before the enrollment or receiving any vaccines within 2 weeks. All participants gave written informed consent prior to study enrollment.

This study was registered in Thai Clinical Trials Registry (thaiclinicaltrials.org, TCTR 20210817003). Immunogenicity parameters were compared with the parallel randomized controlled trial on healthy adult with standard dose and low dose IM administration of AZD1222 booster after completing 2 doses of CoronaVac (TCTR20210722003), conducted at same settings and lab. We compared the results of this study with conventional standard dose (0.5 ml) IM group. Institutional review board of Faculty of Medicine, Chulalongkorn University approved this study (IRB no. 663/64) and parallel IM AZD1222 booster study (IRB no. 600/64).

2.2 Study procedures

One hundred participants were recruited in this study. At baseline, the history of SARS-CoV-2 vaccination and exposure to confirmed case within 3 months were taken. Blood sample was collected prior to giving a booster dose. The participants received ID AZD1222 lot number A1009, manufactured by Siam Bioscience Co., Ltd., 0.1 ml (1×10^{10} viral particles). The vaccination was performed by trained physician/nurse (RN and TT). The solicited local and

systemic reactogenicity during 7 days after vaccination was recorded in the diary. The solicited reactogenicity included fever, pain, swelling, erythema, headache, malaise, myalgia, arthralgia, vomiting, and diarrhea. Scheduled visits were day 14 for 50 participants, day 28 for 50 participants. At day 90, 40 participants were scheduled, to collect reactogenicity data and perform blood collection.

The cell-mediated immunity (CMI) sub study was performed among 20 participants, at baseline, day 28, and day 90, with enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses.

2.3 Immunogenicity outcomes

All participants' samples were tested for spike receptor binding domain (S-RBD) IgG, and functional neutralizing antibody (NAb) against SARS-CoV-2 wild type and delta variants by surrogate virus neutralization test (sVNT). All of the immunogenicity results in ID group were compared with IM participants at equivalent time points.

Quantitative spike receptor binding domain IgG (anti-S-RBD IgG) ELISA

The ELISA protocol was adapted from Amanat *et al.* (2020) [16]. Briefly, diluted serum samples were incubated in 96-well plates coated with purified recombinant Myc-His-tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1). Then, ELISA was performed. Anti-S-RBD IgG level was reported in binding-antibody units (BAU/mL) following conversion of OD450 values with the standard curve using known units of WHO international standard (NIBSC 20/136). We used anti-S-RBD IgG level at 506 BAU/ml, which is correlated with 80% vaccine efficacy reported by the Oxford COVID vaccine trial group [17], as a cut off.

Surrogate virus neutralization test (sVNT)

A surrogate virus neutralization test was set up as previously described in Tan *et al.* (2020) [18]. Recombinant SRBD from the wild-type (Wuhan-Hu-1) and delta (B.1.617.2) strains were used. Serum samples - SRBD mixture were incubated in 96-well plates coated with 0.1 µg/well recombinant human ACE2 ectodomain (GenScript). Then, ELISA was performed. The negative sample was pre-2019 human serum. The % inhibition was calculated as follows:

$$\%inhibition = 100 \times \left[1 - \frac{sampleOD450}{negativeOD450} \right]$$

Enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses

For T cell, ELISpot assay using a Human IFN-γ ELISpotPro™ kit (Mabtech, Stockholm, Sweden) was used for SARS-CoV-2-specific T cell responses in fresh peripheral blood mononuclear cells (PBMCs). Briefly, 2.5 × 10⁵ PBMCs were stimulated in AIM-V medium with overlapping peptide pool from 100 peptides of SARS-CoV-2 Spike (S) defined peptides and 101 peptides from the nucleoprotein (N), membrane protein (M), open reading frame proteins (O) (Mabtech, Stockholm, Sweden) at a final concentration of 2 µg/ml for 20 hours. Negative control and positive control, anti-CD3, were also included. The spots were counted using ImmunoSpot analyzer. Spot counts for negative control wells were subtracted from the test wells to generate normalized readings, these are presented as spot forming unit (SFU) per million PBMCs.

For B cells, Human IgG SARS-CoV-2 RBD ELISpot PLUS (ALP) kit (Mabtech, Stockholm, Sweden) was used for SARS-CoV-2-specific B cell responses. Briefly, the memory B cells were differentiated into antibody secreting cells by pre-stimulating the fresh PBMCs with R848 and IL-2 for 72 hours. Unstimulated well was also used as negative control. Stimulated and

unstimulated PBMCs (5×10^5 cells per well) were added into ELISpot plate and incubated for 18 hours. An RBD-WASP antigen was added into RBD-specific IgG detected well while MT78/145- biotinylated antibodies were added into total IgG detected well, positive control. Anti-WASP-ALP was added into RBD-specific IgG detected well and negative control well while streptavidin-ALP was added into total IgG detected well. Spot counting was performed in the same method as T cells.

2.4 Reactogenicity

Solicited reactogenicity was recorded by participants using diary. All symptoms were graded in 3 grades [19]: grade 0 for no symptom; grade 1 for mild symptom, which was not interfere with activities or vomiting 1 – 2 times/day or diarrhea 2 – 3 times/day; grade 2 for moderate symptom, which interfered with activities or need to take medication, or vomiting more than 2 times/day or diarrhea 4 – 5 times/day; grade 3 for severe symptom, which incapacitated or need hospitalization or diarrhea 6 or more times/day. Fever was graded as grade 1 ($38.0 - 38.4^{\circ}\text{C}$), grade 2 ($38.5 - 38.9^{\circ}\text{C}$), grade 3 ($39 - 40^{\circ}\text{C}$), and grade 4 (more than 40°C). Unsolicited adverse events were also recorded at all visits by study team.

2.5 Statistical analysis

Demographic and clinical characteristics were described for the subjects. Continuous variables were expressed as median (interquartile range: IQR) and number with percentage for categorical variables. Differences in continuous and categorical variables between two groups were assessed using a Wilcoxon rank sum test, Chi-square test, or fisher exact test, respectively. The sVNT results, to either wild type or delta strain, of more than 80% were used to classify the

achievement of 80% protection against symptomatic infection. The anti-S-RBD IgG of more than 506 BAU/ml were used in this study as a cut off for protective antibody level, which previously reported to be associated with 80% vaccine efficacy against primary symptomatic COVID-19 [20].

We presented primary comparisons between ID and IM group in terms of the differences of proportion of participants achieving sVNT $\geq 80\%$ inhibition. Non-inferiority was concluded if the lower bound of the 95% CI did not exceed -10%. Geometric means (GMs) and geometric mean ratios (GMRs) with 95% confidence interval of anti-S-RBD IgG and sVNT, at day 0, 14, 28, and 90 after booster vaccination, were calculated. Non-inferiority was concluded if the lower bound of the 95% CI did not exceed 0.67 for the GMR of anti-S-RBD. All P-values reported are two-sided. Statistical significance was defined as $P < 0.05$. Stata version 15.1 (Stata Corp., College Station, Texas), was used for analysis.

3. Results

3.1 Baseline characteristic

The participants were enrolled during August 2021. The demographic data was shown in Table 1. Median age was 46 (IQR 41-52) years, 55% were male. Underlying disease was described, as shown in Table 1. Duration between 2 doses of CoronaVac was 21 days with median 71 (IQR 65-76) days prior to ID booster administration. The sVNT against delta strain GM was 44.5% inhibition and against wild type was 22.4% inhibition. The number of female were higher in IM cohort, while the interval between completion of 2-dose CoronaVac and AZD1222 booster was longer in ID than IM cohort.

3.2 Reactogenicity

Most common solicited reactogenicity reported was localized at injection site such as erythema and pain, as shown in Figure 1 and Supplementary Table 1. More than half (53%) participants reported erythema, lasting for median duration of 4 (IQR 3-6) days, which was mostly grade 1. Pain at injection site was reported in 43% with median duration of 2 (IQR 1-4) days and mostly grade 1. Other solicited reactogenicity reported were 40% fatigue, 30% myalgia, 27% headache, 18% feverish, 17% swelling, 12% arthralgia and 9% diarrhea. Vesicle and blister at injection site, which progressed to dry blister and turned to hyperpigmentation, were also reported as unsolicited reactogenicity (photo as shown in Supplementary Figure 1).

Lower systemic reactogenicity including fever (0% ID versus 27% IM, $p = \text{N/A}$), feverish (18% ID versus 37% IM, $p = 0.003$), headache (27% ID versus 64% IM, $p < 0.001$), fatigue (40% ID versus 68% IM, $p < 0.001$), and myalgia (30% ID versus 69% IM, $p < 0.001$) was reported in ID compared with IM, as shown in Supplementary Table 1.

3.3 Immunogenicity of ID booster

3.3.1 sVNT

Ninety-eight percent of the participants achieved sVNT against delta strain and wild type $\geq 80\%$ inhibition at both day 14 and day 28. The GMs (95% CI) of sVNT to delta strain were 95.5% inhibition (94.2-96.8) at day 14, and 93.7% inhibition (91.9-95.5) at day 28 after ID booster, as shown in Figure 2 and Table 2. The GMs (95% CI) of sVNT to wild type were 94.8% inhibition (94.0-95.6) at day 14, and 93.7% inhibition (92.1-95.4) at day 28, as shown in Table 2. At day 90 post booster vaccination, the GMs of sVNT, to both delta strain and wild type, waned to 73.1% inhibition (66.7-80.2) and 81.9% inhibition (76.2-88.0), respectively.

3.3.2 Anti-S-RBD IgG

The GMs (95% CI) of anti-S-RBD IgG were 2037.1 (1770.9-2343.2), 1084.9 (970.0-1213.4), and 744.6 (650.1-852.9) BAU/mL at day 14, 28, and 90 after ID booster, respectively, as shown in Table 2.

3.4 Immunogenicity of ID compared with IM booster

Proportion of participants with sVNT to delta strain $\geq 80\%$ inhibition at day 14 was non-inferior among ID recipients compared with IM recipients, with difference of 4.2% (95% CI -2.0 to 10.5). But at day 90, it was significantly lower, with difference of -37.3% (-54.2 to -20.3). These differences were similar to sVNT to wild type, as shown in Table 2. GMR of anti-S-RBD IgG showed non-inferiority at day 14, with GMR of 0.99 (0.83-1.20), and borderline inferior at day

90, with GMR of 0.82 (0.66-1.02). However, at 90 days after ID vaccination, only 79.5% had antibody exceeding the proposed protective level, compared with 83.8% of IM recipients.

3.5 T and B cell responses evaluated by ELISpot assay

From the sub study analysis of CMI response, ELISpot assay showed significant rise of T cell and B cell response at day 28 and declined at day 90, as shown in Figure 3. Median (IQR) of IFN- γ -producing T cell spots specific to SNMO protein-derived peptide pools at day 0 was 32 (14-56), at day 28 was 146 (70-192), and at day 90 was 90 (20-140) SFU/ 10^6 PBMCs, respectively. Compared with IM study, the median (IQR) was 52 (40-48) at day 0, 96 (44-128) at day 28, and 44 (32-72) SFU/ 10^6 PBMCs at day 90, respectively. Median (IQR) of RBD-specific memory B cell spots at day 0 was 2 (0-10), increased to 18 (14-36) at day 28, and declined to 6 (4-20) SFU/ 10^6 PBMCs at day 90. Compared with IM study of 4 (0-16) at day 0, 26 (16-32) at day 28, and 8 (4-16) SFU/ 10^6 PBMCs at day 90.

4. Discussion

ID AZD1222 booster vaccine in 2-dose-CoronaVac-primed adults raised high anti-S-RBD IgG >506 BAU/ml, and high levels of functional neutralizing antibodies >80% inhibition as measured by sVNT to wild type and delta strain, thus non-inferior to IM route at day 14. However, at 3 months post ID AZD1222 booster vaccination, this study demonstrated, despite similar anti-S-RBD IgG, but lower sVNT against delta strain to IM booster, suggesting more rapid waning neutralizing antibody response after ID compared to IM route. Most reactogenicity occurred locally with erythema, pain, and swelling at injection site. Erythema, swelling, and blister were reported more common in ID booster. Systemic symptoms such as fever, feverish, headache, fatigue, and myalgia were less common than conventional IM injection.

The non-inferior immunogenicity of ID vaccination was demonstrated for influenza, rabies, and hepatitis B vaccines [21]. Immunogenicity of ID AZD1222 at day 14 was not inferior to conventional IM booster vaccine as shown with GMR of anti-S-RBD and difference in proportion of participants having sVNT to delta strain and wild type passing 80%. This comparable result is similar to previous study in Netherland [22] which reported a robust antibody response from ID administration of mRNA COVID-19 vaccine at day 43 with comparable anti-spike IgG response for 10 µg ID with 100 µg IM mRNA-1273 vaccine. Additionally, recent report from Thailand also denoted a fractional-dose BNT162b2 ID booster, in healthy adults who had completed 2-dose inactivated vaccine for 2-3 months, induced comparable antibody level and function to the conventional IM booster when assessed on day 14 and 28 [14]. To our knowledge, no published report demonstrated immunogenicity results at 3 months post ID AZD1222 booster vaccination, which this study demonstrated inferior neutralizing antibodies.

Although, the importance of cellular immunity in correlation with vaccine protection is still unclear, specific T cells have been reported to reduce the severity of SARS-CoV-2 infection [23]. In this study, we have shown that a third dose of ID AZD1222 booster vaccine can increase specific T cell responses slightly higher than conventional IM route, similar to the previous report [24]. As opposed to previous ID BNT162b2 study, which failed to demonstrate T cell response, suggesting different vaccine platforms might play a role in cellular immune response. Specific memory B cells also have been reported to play a crucial role for effective responses to infection [25, 26]. Our result showed the slight boost of B cell response at 1 month and drop at 3 months, after ID AZD1222 booster. The timing of B cell study might be accounted for these responses, since the previous study showed the detectable B cell response after COVID-19 infection for 3-6 months [27].

This study reported local reactogenicity including erythema, blister, and pruritus after ID AZD1222 booster vaccine which is similar to previous report on rabies inactivated vaccine that more erythema and pruritus were reported from ID than conventional IM administration [28]. Also blister formation was reported after BCG vaccination that evolved over two weeks into an ulcer at injection site [29]. ID influenza vaccine study reported significant higher local adverse events particularly erythema and swelling, and also more common of fever and chills which is different from this study that fever was more common in IM vaccination [9]. Hyperpigmentation was also reported in this study as still seen on day 28 follow up visit which previous study of hepatitis B vaccine reported of local hyperpigmentation after ID vaccination in 55% [30]. Compared with parallel cohort IM study, ID booster had more local reactogenicity (erythema and swelling) at injection site but less pain and systemic reactogenicity (fatigue, myalgia, headache, feverish, arthralgia and diarrhea).

As current situation of COVID-19 pandemic, more vaccine supply is still needed for many countries as vaccine coverage is not enough to prevent mortality [31-33]. Almost half of the world population has received at least one dose of COVID-19 vaccine but only 2.2% of people in low-income countries have received vaccine [34]. AZD1222 or Astra Zeneca/Oxford COVID-19 vaccine has been used in Europe since December 2020 and also distributed in many countries including low to middle income countries [35]. As availability in many countries with limited vaccine supply, the ID administration of AZD1222 might be considered for mass vaccination as an advantage of dose-sparing technique [7]. However, there are some limitations, needs of skilled health providers for administration [36], and more rapid waning of neutralizing antibodies.

This study was limited by cohort study design without randomized control trial but there was the parallel cohort study with similar setting that should be able to benchmark the results. There were 2 factors that differed between the 2 groups. Specifically, there was more male in the ID group and the time interval between second and third dose was 1 week longer in the ID group. However, the immune responses at baseline before the third dose were comparable. Female was reported to have higher antibody response to vaccines [37] and after severe COVID-19 [38]. The finding of later inferior neutralizing antibodies might be attributed to this gender difference, specifically more male participants in ID cohort. This study chose to determine the levels of functional neutralizing antibodies using the surrogate virus neutralization assay, rather than standard live-virus neutralization assay. However, we used the high cut-off value at 80% of sVNT in this study. Moreover, good correlations between sVNT and live-virus neutralization have been exhibited elsewhere [18, 39-41]. The strengths of this study were reporting complete solicited reactogenicity of all 100 participants with ID booster vaccination and multiple methods

were used for immunity analysis including anti-S-RBD, sVNT (wild type and delta strain) and also CMI responses.

Intradermal AZD1222 booster vaccine in 2-dose-CoronaVac primed adult enhanced comparable short-term immunity, but inferior 3-month immunogenicity, with intramuscular administration. Reactogenicity was usually localized (erythema and pain) and less systemic than intramuscular vaccine. Due to more rapid waning neutralizing antibody, dose-sparing strategy with intradermal booster vaccination should be used in the setting of inadequate vaccine supply.

Acknowledgements

Thank you for all study teams for their assistance with the study.

Chulalongkorn University Health Service Center

Santhiti Dahlan, M.D., Preeyanuch Panchim, Ratchadaporn Bumrungpipattanaporn, RN,

Ampawan Sangchanpong, Wijitra Prayong

Department of Microbiology, Faculty of Medicine, Chulalongkorn University

Asst.Prof.Pokrath Hansasuta, M.D., Vichaya Ruenjaiman, PhD, Supapit Horpratum,

Jullada Thawilwang

Center of Excellence in Pediatric Infectious Diseases and Vaccines

Pintip Suchartlikitwong, M.D., Wipaporn Natalie Songtaweasin, M.D., Pathariya

Promsena, M.D., Monta Tawan, RN, Jitthiwa Athipunjapong, RN, Thutsanun

Meepuksom, RN, Angsumalin Sutjarit, RN, Juthamanee Moonwong, Rachaneekorn

Nadsasarn, Thidarat Jupimai, Pornpavee Nuncharoen, Sasiprapha Khamthi, Pathomchai

Amornrattanapajit, Phattharapa Khamkhen,

National Center for Genetic Engineering and Biotechnology (BIOTEC)

Anan Jongkaewwattana, PhD, Kirana Yoohat, Channarong Seepiban, Jaraspim Narkpuk,

Thorntun Deangphare,

Clinical Research Laboratory, Faculty of Medicine, Chulalongkorn University

Palida Pingthaisong, Suwat Wongmueng

Faculty of Medicine, Thammasat University

Asst.Prof.Sira Nantapisal, M.D., Ph.D.

Funding

The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under Health Research Platform (RA64/050), Chulalongkorn University. This research is also supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Table 1. Baseline characteristics of participants receiving AZD1222 booster vaccine after 2-dose CoronaVac in healthy adults

Characteristic	ID (N = 100)	IM (N = 100)	p-value
Gender			
• Female, n (%)	45 (45)	61 (61)	0.02 ^{†*}
Age (years)	46 (41-52)	45 (34-50)	0.08 [‡]
BMI (kg/m ²)	24.8 (21.4-27.4)	24.1 (21.6-26.9)	0.37 [‡]
Underlying disease, n (%)	19 (19)	29 (29)	0.10 [†]
• Hypertension, n (%)	7 (7)	9 (9)	0.60 [†]
• Dyslipidemia, n (%)	6 (6)	7 (7)	0.77 [†]
• Diabetes mellitus, n (%)	6 (6)	3 (3)	0.31 [†]
• Allergic rhinitis, n (%)	1 (1)	2 (2)	0.56 [†]
Duration of 2 nd doses of CoronaVac and AZD1222 (days)	71 (65-76)	66 (62-74)	0.002 ^{‡*}
Immunogenicity at baseline prior to booster			
• sVNT-delta (% inhibition), GM (95%CI)	22.4 (18.7-26.9)	17.9 (14.3-22.5)	0.14 [§]
• sVNT-WT (% inhibition), GM (95%CI)	44.5 (40.6-48.7)	41.8 (37.1-47.1)	0.41 [§]
• Anti-S-RBD (BAU/mL), GM (95%CI)	109.3 (95.4-125.1)	98.9 (85.8-113.9)	0.31 [§]
• SNMO-specific T cell response (SFU/10 ⁶ PBMCs)	32 (14-56) (n = 20)	52 (40-84) (n = 19)	0.05 [‡]
• RBD-specific B cell response (SFU/10 ⁶ PBMCs)	2 (0-10) (n = 20)	4 (0-16) (n = 19)	0.50 [‡]

All data are reported as median (IQR), unless otherwise indicated.

417 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, BMI: Body
 418 mass index, GM: Geometric mean, ID: intradermal, IM: intramuscular, IQR: interquartile range,
 419 RBD: receptor binding domain, SNMO: Spike (S) nucleoprotein (N), membrane protein (M),
 420 and open reading frame proteins (O) of SARS-CoV-2, sVNT-delta: Surrogate virus
 421 neutralization test against delta strain, sVNT-WT: Surrogate virus neutralization test against wild
 422 type
 423 [†]Chi-square
 424 [‡]Wilcoxon rank sum test
 425 [§]Two sample independent t test
 426 *p < 0.05

Table 2. Comparison of intradermal and intramuscular AZD1222 booster immunogenicity in healthy adult completing 2-dose CoronaVac

	ID	IM	GM Ratio
	GM (95%CI)	GM (95%CI)	(95%CI)
Day 14	N=50	N=100	
• Anti-S-RBD (BAU/mL)	2037.1 (1770.9-2343.2)	2043.2 (1824.5-2288.2)	0.99 (0.83-1.20)
• sVNT-Delta (% inhibition)	95.5 (94.2-96.8)	94.7 (92.4-97.1)	1.01 (0.97-1.04)
• sVNT-WT (% inhibition)	94.8 (94.0-95.6)	96.7 (94.9-98.4)	0.98 (0.96-1.01)
Day 28	N=50	N=24	
• Anti-S-RBD (BAU/mL)	1084.9 (970-1213.4)	1499.5 (1166.6-1927.4)	0.72 (0.57-0.91)
• sVNT-Delta (% inhibition)	93.7 (91.9-95.5)	88.5 (80.1-97.7)	1.06 (0.99-1.14)
• sVNT-WT (% inhibition)	93.7 (92.1-95.4)	91.5 (85.9-97.4)	1.02 (0.98-1.08)
Day 90	N=39	N=99	
• Anti-S-RBD (BAU/mL)	744.6 (650.1-852.9)	909 (802.1-1030.1)	0.82 (0.66-1.02)
• sVNT-Delta (% inhibition)	73.1 (66.7-80.2)	92.8 (90.2-95.4)	0.79 (0.73-0.85)
• sVNT-WT (% inhibition)	81.9 (76.2-88.0)	94.6 (92.4-96.9)	0.87 (0.82-0.92)
	% (95%CI)	% (95%CI)	% difference (95%CI)
Day 14	N=50	N=100	
• Anti-S-RBD $\geq$ 506 BAU/ml [†]	100.0 (92.8-100.0)	97.0 (91.5-99.4)	3.0 (-0.3 to 6.3)
• sVNT-Delta $\geq$ 80% inhibition	98.0 (89.1-99.9)	93.8 (86.9-97.6)	4.2 (-2.0 to 10.5)
• sVNT-WT $\geq$ 80% inhibition	100.0 (92.8-100.0)	95.8 (89.7-98.9)	4.2 (0.01 to 8.2)
Day 28	N=50	N=24	
• Anti-S-RBD $\geq$ 506 BAU/ml [†]	98.0 (89.4-99.9)	96.0 (79.6-99.8)	2.0 (-6.6 to 10.6)
• sVNT-Delta $\geq$ 80% inhibition	98.0	91.7	6.3

	(89.4-99.9)	(73.0-98.9)	(-5.4 to 18.1)
• sVNT-WT $\geq$ 80% inhibition	98.0 (89.4-99.9)	91.7 (73.0-98.9)	6.3 (-5.4 to 18.1)
Day 90	N=39	N=99	
• Anti-S-RBD $\geq$ 506 BAU/ml [†]	79.5 (63.5-90.7)	83.8 (75.1-90.5)	-4.4 (-18.9 to 10.2)
• sVNT-Delta $\geq$ 80% inhibition	52.6 (35.8-69)	89.9 (82.2-95)	-37.3 (-54.2 to -20.3)
• sVNT-WT $\geq$ 80% inhibition	68.4 (51.3-82.5)	90.9 (83.4-95.7)	-22.5 (-38.3 to -6.7)

429

430 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, GM: Geometric
 431 mean, ID: intradermal, IM: intramuscular, sVNT-delta: Surrogate virus neutralization test against
 432 delta strain, sVNT-WT: Surrogate virus neutralization test against wild type

433 [†]Anti-S-RBD IgG 506 BAU/ml correlated with 80% vaccine efficacy as reported by Feng, et al
 434 [17].

435

436

Figure 1. Solicited reactogenicity within 7 days of ID and IM AZD1222 booster after 2-dose CoronaVac in healthy adult.
ID: intradermal, IM: intramuscular

Figure 2. Comparison of sVNT % inhibition against delta strain at day 0, 14, 28, and 90 of ID and IM AZD1222 booster after 2-dose of CoronaVac in healthy adult.

ID: intradermal, IM: intramuscular, sVNT: Surrogate virus neutralization test

448 (A) SNMO-specific T cell response

449

450 (B) RBD-specific B cell response

451

452

453 **Figure 3.** ELISpot assay at day 0, day 28, and day 90 of ID and IM AZD1222 booster in healthy
 454 adult completing 2-dose CoronaVac: (A) Interferon- γ ELISpot response to SNMO overlapping
 455 peptides of SARS-CoV-2, (B) RBD-specific IgG ELISpot assay.
 456 ID: intradermal, IM: intramuscular, RBD: receptor binding domain, SFU: spot forming unit,
 457 SNMO: Spike (S) nucleoprotein (N), membrane protein (M), and open reading frame proteins
 458 (O) of SARS-CoV-2

459

Supplementary Table 1. Solicited reactogenicity within 7 days of ID and IM AZD1222 booster after 2-dose CoronaVac in healthy adult.

Reactogenicity, n (%)	ID (N=100)	IM (N=100)	P-value
Local reactogenicity			
Pain	43 (43)	82 (82)	<0.001*
• Mild	41 (41)	67 (67)	
• Moderate	2 (2)	13 (13)	
• Severe	0	2 (2)	
• Duration (days), median (IQR)	2 (1-4)	3 (2-5)	0.12
Swelling	17 (17)	3 (3)	0.002*
• Mild	15 (15)	1 (1)	
• Moderate	1 (1)	2 (2)	
• Severe	1 (1)	0	
• Duration (days), median (IQR)	6 (5-8)	4 (3-6)	0.28
Redness	53 (53)	3 (3)	<0.001*
• Mild	47 (47)	0 (0)	
• Moderate	5 (5)	2 (2)	
• Severe	1 (1)	1 (1)	
• Duration (days), median (IQR)	4 (3-6)	5 (1-6)	0.35
Systemic reactogenicity			
Fever (BT≥38°C)	0	27 (27)	NA
• Mild	0	10 (10)	
• Moderate	0	12 (12)	
• Severe	0	5 (5)	
• Duration (days), median (IQR)	-	2 (1-2)	NA
Feverish	18 (18)	37 (37)	0.003*
• Mild	16 (16)	27 (27)	
• Moderate	2 (2)	10 (10)	
• Duration (days), median (IQR)	1 (1-2)	1 (1-2)	0.93
Headache	27 (27)	64 (64)	<0.001*
• Mild	17 (17)	37 (37)	
• Moderate	10 (10)	24 (24)	

• Severe	0	3 (3)	
• Duration (days), median (IQR)	2 (1-2)	2 (1-3)	0.15
Fatigue	40 (40)	68 (68)	<0.001*
• Mild	36 (36)	42 (42)	
• Moderate	4 (4)	22 (22)	
• Severe	0 (0)	4 (4)	
• Duration (days), median (IQR)	1 (1-2)	2 (2-3)	0.61
Myalgia	30 (30)	69 (69)	<0.001*
• Mild	27 (27)	35 (35)	
• Moderate	3 (3)	31 (31)	
• Severe	0 (0)	3 (3)	
• Duration (days), median (IQR)	2 (2-3)	2 (2-3)	0.60
Arthralgia	12 (12)	21 (21)	0.09
• Mild	8 (8)	15 (15)	
• Moderate	4 (4)	5 (5)	
• Severe	0 (0)	1 (1)	
• Duration (days), median (IQR)	2 (2-3)	2 (1-2)	0.06
Vomiting	0	4 (4)	NA
• Mild	0	4 (4)	
• Moderate	0	0 (0)	
• Severe	0	0 (0)	
• Duration (days), median (IQR)	0	1 (1-1)	NA
Diarrhea	9 (9)	12 (12)	0.49
• Mild	8 (8)	11 (11)	
• Moderate	1 (1)	1 (1)	
• Duration (days), median (IQR)	1 (1-3)	1 (1-2)	0.43

462

463 ID: intradermal, IM: intramuscular

464 *p < 0.05

465

Supplementary Figure 1. Photography of local reactogenicity in participants receiving intradermal AZD1222 booster after completing 2-dose CoronaVac: (A) local reactogenicity in participants: i-ii) erythematous patch at injection site at day 4, iii) residual post inflammatory

471 hyperpigmented macule and iv) erythematous patch at injection site at day 28 and (B) a serial
472 photography day 1-7 in single participant: Day 1 erythematous patch at injection site, Day 2
473 central swelling on erythematous patch, Day 3-6 blister forming at central of erythematous patch,
474 and Day 7 dry blister with necrotic crust on erythematous base.

References

1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from: <https://covid19.who.int/>. Accessed date 28 November, 2021.
2. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med* 2021. <https://doi.org/10.1056/NEJMoa2107715>
3. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *Lancet Reg Health Am* 2021;100025. <https://doi.org/10.1016/j.lana.2021.100025>
4. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. *Lancet Infect Dis* 2021. [https://doi.org/10.1016/S1473-3099\(21\)00568-5](https://doi.org/10.1016/S1473-3099(21)00568-5)
5. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet* 2021;398:856-69. [https://doi.org/10.1016/S0140-6736\(21\)01694-9](https://doi.org/10.1016/S0140-6736(21)01694-9)
6. Benning L, Tollner M, Hidmark A, Schaier M, Nussbag C, Kalble F, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. *Vaccines (Basel)* 2021;9. <https://doi.org/10.3390/vaccines9080857>
7. Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? *Risk Manag Healthc Policy* 2021;14:2079-87. <https://doi.org/10.2147/RMHP.S309707>

- 498 8. Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques,
499 Challenges, and Prospects. *Vaccines (Basel)* 2020;8. <https://doi.org/10.3390/vaccines8030534>
- 500 9. Egunsola O, Clement F, Taplin J, Mastikhina L, Li JW, Lorenzetti DL, et al.
501 Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines:
502 A Systematic Review and Meta-analysis. *JAMA Netw Open* 2021;4:e2035693.
503 <https://doi.org/10.1001/jamanetworkopen.2020.35693>
- 504 10. World Health O. Polio vaccines: WHO position paper, March 2016-recommendations.
505 *Vaccine* 2017;35:1197-9. <https://doi.org/10.1016/j.vaccine.2016.11.017>
- 506 11. World Health O. WHO Expert Consultation on Rabies. Second report. World Health
507 Organ Tech Rep Ser 2013:1-139, back cover.
- 508 12. World Health O. Rabies vaccines: WHO position paper, April 2018 - Recommendations.
509 *Vaccine* 2018;36:5500-3. <https://doi.org/10.1016/j.vaccine.2018.06.061>
- 510 13. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.
511 Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273
512 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. *medRxiv*
513 2021:2021.07.27.21261116. <https://doi.org/10.1101/2021.07.27.21261116>
- 514 14. Intapiboon PS, P.; Ongarj, J.; Surasombatpattana, S.; Uppanisakorn, S.;
515 Mahasirimongkol, S.; Sawaengdee, W.; Phumiamorn, S.; Sapsutthipas, S.; Sangsupawanich, P.;
516 Chusri, S.; Pinpathomrat, N. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
517 Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
518 *Vaccines* 2021. <https://doi.org/10.3390/vaccines9121375>

15. Singhatiraj E, Pongpirul K, Jongkaewwattana A, Hirankarn N. Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report. *Vaccines* 2021;9:990. <https://doi.org/10.3390/vaccines9090990>
16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 2020;26:1033-6. <https://doi.org/10.1038/s41591-020-0913-5>
17. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 2021. <https://doi.org/10.1038/s41591-021-01540-1>
18. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 2020;38:1073-8. <https://doi.org/10.1038/s41587-020-0631-z>
19. U.S. Department of Health and Human Services F, CBER. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials September 2007 [Available from: <https://www.fda.gov/media/73679/download>. Accessed date 30 November, 2021.
20. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine* 2021. <https://doi.org/10.1038/s41591-021-01540-1>
21. Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijns C, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. *Travel Med Infect Dis* 2020;37:101868. <https://doi.org/10.1016/j.tmaid.2020.101868>

22. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al. Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021. <https://doi.org/10.1101/2021.07.27.21261116>
23. Noh JY, Jeong HW, Kim JH, Shin EC. T cell-oriented strategies for controlling the COVID-19 pandemic. Nat Rev Immunol 2021. <https://doi.org/10.1038/s41577-021-00625-9>
24. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Front Immunol 2021;12:645210. <https://doi.org/10.3389/fimmu.2021.645210>
25. Jahnmatz P, Sundling C, Makower B, Sonden K, Farnert A, Ahlborg N. Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot. J Immunol Methods 2020;478:112715. <https://doi.org/10.1016/j.jim.2019.112715>
26. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine. Front Immunol 2021;12:740708. <https://doi.org/10.3389/fimmu.2021.740708>
27. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) 2021;2:281-95 e4. <https://doi.org/10.1016/j.medj.2021.02.001>
28. Angsuwatcharakon P, Ratananpinit N, Yoksan S, Saengseesom W, Sriaksorn R, Raksahket N, et al. Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country. Vaccine 2020;38:5015-20. <https://doi.org/10.1016/j.vaccine.2020.05.054>

- 565 29. Fritz TM, Trueb RM. [BCG ulcer. Rapid healing with topical INH powder]. *Hautarzt*
566 2002;53:816-8. <https://doi.org/10.1007/s00105-002-0367-3>
- 567 30. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and
568 intramuscular administration of hepatitis B vaccine in neonates. *Indian J Gastroenterol*
569 2001;20:94-6.
- 570 31. Blanchet K, Mallard G, Moret E, Sun J. Sanctioned countries in the global COVID-19
571 vaccination campaign: the forgotten 70. *Confl Health* 2021;15:69.
572 <https://doi.org/10.1186/s13031-021-00404-2>
- 573 32. Perry M, Akbari A, Cottrell S, Gravenor MB, Roberts R, Lyons RA, et al. Inequalities in
574 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales,
575 UK. *Vaccine* 2021. <https://doi.org/10.1016/j.vaccine.2021.09.019>
- 576 33. Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in
577 Brazilian elderly. *Rev Bras Epidemiol* 2021;24:e210041. [https://doi.org/10.1590/1980-](https://doi.org/10.1590/1980-549720210041)
578 549720210041
- 579 34. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
580 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus
581 Pandemic (COVID-19): Our World in Data; 2020 [cited 2021 26 sep 2021]. Available from:
582 <https://ourworldindata.org/covid-vaccinations>. Accessed date 26 September, 2021.
- 583 35. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused
584 review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. *Int*
585 *Immunopharmacol* 2021;100:108162. <https://doi.org/10.1016/j.intimp.2021.108162>
- 586 36. Schweiger M. Intradermal covid-19 vaccination could solve supply problems. *BMJ*
587 2021;374:n1980. <https://doi.org/10.1136/bmj.n1980>

- 588 37. Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences
589 and age. *Womens Health (Lond)* 2021;17:17455065211022262.
590 <https://doi.org/10.1177/17455065211022262>
- 591 38. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG
592 antibody between male and female COVID-19 patients: A possible reason underlying different
593 outcome between sex. *J Med Virol* 2020;92:2050-4. <https://doi.org/10.1002/jmv.25989>
- 594 39. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple
595 protein-based surrogate neutralization assay for SARS-CoV-2. *JCI Insight* 2020;5.
596 <https://doi.org/10.1172/jci.insight.142362>
- 597 40. Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke GJ, Yerly S, et al. Validation and
598 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). *Emerg*
599 *Microbes Infect* 2020;9:2394-403. <https://doi.org/10.1080/22221751.2020.1835448>
- 600 41. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, et al.
601 Evaluation of a commercially-available surrogate virus neutralization test for severe acute
602 respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis*
603 2021;99:115294. <https://doi.org/10.1016/j.diagmicrobio.2020.115294>